Science Foundation Arizona (SFAz) encourages Community College Hispanic Serving Institutions (HSIs) that meet eligibility requirements to apply for Cohort 3 of the KickStarter Program with support by National Science Foundation (NSF HRD# 1450061).
It is well-recognized that patients receiving carboplatin as second-line treatment of ovarian. cancer have at least a modest risk for experiencing hypersensitivity reactions.1 The onset of. reactions is unpredictable and they could occur immediately upon initiation of the drug infusion. or may not be seen until one half or more of the infusion has been administered to the patient. On the other hand, the onset of the reactions has also been reported in patients receiving more. than six cumulative courses. The symptoms associated with the reactions range from a minor. rash to diffuse erythroderma, pruritis, severe anxiety, dyspnea, tachycardia, hypotension, and in. severe cases, death.
Type 4 hypersensitivity is often called delayed type hypersensitivity as the reaction takes two to three days to develop. Unlike the other types, it is not antibody mediated but rather is a type of cell-mediated response.CD4+ helper T cells recognize antigen in a complex with Class II major histocompatibility complex.ctivated CD8+ T cells destroy target cells on contact, whereas activated macrophages produce hydrolytic enzymes and, on presentation with certain intracellular pathogens, transform into multinucleated giant cells.